Nature Medicine has published a manuscript detailing promising results from Biogen’s multiple ascending dose Phase 1b trial, which evaluated the safety, pharmacokinetics and target engagement of Biogen’s BIIB080 (MAPT ASO), an investigational antisense oligonucleotide targeting tau mRNA in early-stage Alzheimer’s disease (AD).
These early stage data support our commitment to building on a deep expertise in Alzheimer’s Disease by advancing Biogen’s industry-leading Alzheimer's pipeline across therapeutic modalities and molecular targets.
A link to the manuscript is provided here: https://www.nature.com/articles/s41591-023-02326-3
Currently, the Phase 2 CELIA study of BIIB080 (NCT05399888) is in progress and recruiting participants in the United States.
In December 2019, Biogen exercised a license option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO).